|1.||Solomon, Richard: 5 articles (10/2014 - 06/2009)|
|2.||Jost, Gregor: 4 articles (12/2014 - 04/2011)|
|3.||Pietsch, Hubertus: 4 articles (12/2014 - 04/2011)|
|4.||Aspelin, Peter: 4 articles (07/2012 - 02/2005)|
|5.||Chai, Chun-Ming: 4 articles (11/2010 - 08/2002)|
|6.||Prasad, Pottumarthi V: 3 articles (10/2014 - 11/2012)|
|7.||Li, Lu-Ping: 3 articles (10/2014 - 11/2012)|
|8.||Franklin, Tammy: 3 articles (10/2014 - 11/2012)|
|9.||Soulez, Gilles: 3 articles (03/2011 - 11/2006)|
|10.||Heiken, Jay P: 3 articles (07/2008 - 11/2006)|
11/15/2014 - "Iso-osmolar contrast (iodixanol) reduces patient and operator pain during peripheral angiography."
01/01/2011 - "A greater reduction in the magnitude of pain was observed with IOCM (iodixanol), particularly with selective limb and carotid/intracerebral procedures. "
07/01/1997 - "Further, 4.1% in the iodixanol group experienced pain and/or severe heat sensation vs 19. "
10/01/2010 - "To determine prospectively the incidence and nature of immediate and delayed adverse drug reactions occurring after administration of iodixanol for contrast-enhanced computed tomography (CT) in routine practice in nonselected patients, and to assess patient comfort (pain and sensations of heat or coldness). "
09/01/1996 - "The results of this study support the conclusion that iodixanol at 320 mg I/kg is safe and effective for adult aortography and peripheral arteriography and causes significantly less injection-related pain than ioxaglate."
|2.||Renal Insufficiency (Renal Failure)
07/01/2007 - "Our study was a retrospective evaluation comparing the incidence of contrast-induced nephropathy in consecutive patients with underlying renal insufficiency undergoing diagnostic CT examinations receiving iodixanol from November 2003 to June 2005 with a comparison group of patients with normal baseline renal function over the same period. "
11/01/2013 - "Using clinically healthy cattle and those with renal failure, the GFR values estimated from the Holstein equation were in good agreement with those by the multisample method using iodixanol (r=0.89, P=0.01). "
11/22/2012 - "Only one patient showed renal failure, one week after dosing with iodixanol. "
07/01/2007 - "The risk of contrast-induced nephropathy is significantly higher in patients with underlying renal insufficiency receiving iodixanol than that for patients with normal baseline renal function, but this should not serve as an absolute contraindication for these patients to receive intravenous iodinated contrast for diagnostic CT examinations particularly in patients with life-threatening clinical questions in which contrasted CT may provide valuable information."
07/01/2007 - "In the group of patients receiving iodixanol with underlying renal insufficiency (189 patients), 9.0% developed contrast nephropathy (P = 0.015) with 4.8% of patients developing irreversible renal damage (P = 0.03). "
|3.||Acute Coronary Syndrome
11/01/2002 - "In patients with an acute coronary syndrome, there was a trend toward a reduced incidence of the combined endpoint in the Hexabrix compared to the Visipaque group, although this did not reach statistical significance (17.2% vs. 24.8%; P = 0.17). "
01/01/2013 - "The aim of this study is to compare iodixanol and iopamidol in patients with acute coronary syndrome (ACS) who are currently undergoing coronary angiography. "
01/01/2013 - "[Nephrotoxicity of iodixanol versus iopamidol in patients with acute coronary syndrome]."
11/01/2012 - "Additionally, iodixanol induced a dose-dependent increase in renal medullary hypoxia."
05/01/2012 - "Functional MR imaging of the kidneys demonstrates increased R2* in the inner medulla only after the administration of the iodixanol potentially indicating hypoxia and thus a pathomechanism of contrast-induced nephropathy."
01/01/2014 - "Compared with iodixanol, iohexol induced a significantly greater reduction in renal function, severe renal tissue damage, intrarenal hypoxia, and apoptotic tubular cells. "
07/01/2002 - "Iodixanol produced a more sustained medullary hypoxia than ioxaglate when injected selectively into the dog renal artery. "
07/01/2002 - "The hypoperfusion and hypoxia lasted significantly longer with iodixanol than with ioxaglate. "
11/01/1995 - "At the dose level of 1.0 ml/kg b.w., iodixanol produced no seizures but did cause focal twitching in 4/10 rabbits. "
05/01/1995 - "Iotrolan induced generalized seizures in 5 rabbits, iodixanol 320 mg I/ml in 2 rabbits, and iodixanol 150 mg I/ml in one rabbit. "
11/01/1995 - "Iotrolan produced generalised grand mal seizures in 8/10 rabbits, an incidence of excitation significantly greater than that of iodixanol (p < 0.01) and iopamidol (p < 0.05). "
10/01/1995 - "1) Iodixanol administered intravenously over a dose range of 320 to 3,200 mgI/kg had little or no effect on the general behavior, spontaneous locomotor activity, hexobarbital sleeping time, pain response, electroshock- or pentylenetetrazol-induced convulsion (mouse), EEG or body temperature (rabbit), gastrointestinal propulsion (mouse) or skeletal muscle contraction (rabbit). "
|1.||Ioxaglic Acid (Ioxaglate Meglumine)
|2.||Angioplasty (Angioplasty, Transluminal)